IntelGenx Technologies Corp. Logo

IntelGenx Technologies Corp.

IGXT

(1.8)
Stock Price

0,17 USD

-210.55% ROA

229.31% ROE

-1.74x PER

Market Cap.

29.709.326,00 USD

-142.44% DER

0% Yield

-2173.28% NPM

IntelGenx Technologies Corp. Stock Analysis

IntelGenx Technologies Corp. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

IntelGenx Technologies Corp. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (345.35%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

The stock's low PBV ratio (-2.67x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a minimal amount of debt (-155%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

5 ROA

The stock's ROA (-220.91%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

IntelGenx Technologies Corp. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

IntelGenx Technologies Corp. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

IntelGenx Technologies Corp. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

IntelGenx Technologies Corp. Revenue
Year Revenue Growth
2003 0
2004 0 0%
2005 0 0%
2006 265.901 100%
2007 835.415 68.17%
2008 976.610 14.46%
2009 1.278.700 23.62%
2010 1.337.000 4.36%
2011 440.000 -203.86%
2012 1.208.000 63.58%
2013 948.000 -27.43%
2014 1.659.000 42.86%
2015 5.095.000 67.44%
2016 5.220.000 2.39%
2017 5.195.000 -0.48%
2018 1.824.000 -184.81%
2019 742.000 -145.82%
2020 1.544.000 51.94%
2021 1.535.000 -0.59%
2022 950.000 -61.58%
2023 1.272.000 25.31%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

IntelGenx Technologies Corp. Research and Development Expenses
Year Research and Development Expenses Growth
2003 0
2004 0 0%
2005 0 0%
2006 510.407 100%
2007 603.402 15.41%
2008 2.085.433 71.07%
2009 1.421.700 -46.69%
2010 1.565.000 9.16%
2011 1.336.000 -17.14%
2012 1.723.000 22.46%
2013 561.000 -207.13%
2014 1.075.000 47.81%
2015 1.033.000 -4.07%
2016 1.766.000 41.51%
2017 2.615.000 32.47%
2018 5.104.000 48.77%
2019 3.774.000 -35.24%
2020 2.637.000 -43.12%
2021 2.717.000 2.94%
2022 3.031.000 10.36%
2023 3.468.000 12.6%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

IntelGenx Technologies Corp. General and Administrative Expenses
Year General and Administrative Expenses Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 1.459.844 100%
2009 1.381.300 -5.69%
2010 2.730.000 49.4%
2011 1.513.000 -80.44%
2012 1.645.000 8.02%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

IntelGenx Technologies Corp. EBITDA
Year EBITDA Growth
2003 -108
2004 -7.545 98.57%
2005 -9.906 23.83%
2006 -773.716 98.72%
2007 -574.052 -34.78%
2008 -2.140.060 73.18%
2009 -1.241.700 -72.35%
2010 -2.958.000 58.02%
2011 -2.409.000 -22.79%
2012 -2.160.000 -11.53%
2013 -1.567.000 -37.84%
2014 -1.706.000 8.15%
2015 1.585.000 207.63%
2016 -466.000 440.13%
2017 -1.747.000 73.33%
2018 -8.268.000 78.87%
2019 -8.735.000 5.35%
2020 -5.108.000 -71.01%
2021 -7.039.000 27.43%
2022 -8.632.000 18.45%
2023 -11.036.000 21.78%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

IntelGenx Technologies Corp. Gross Profit
Year Gross Profit Growth
2003 0
2004 0 0%
2005 0 0%
2006 265.901 100%
2007 835.415 68.17%
2008 976.610 14.46%
2009 1.278.700 23.62%
2010 1.337.000 4.36%
2011 440.000 -203.86%
2012 1.208.000 63.58%
2013 948.000 -27.43%
2014 1.659.000 42.86%
2015 4.662.000 64.41%
2016 4.901.000 4.88%
2017 4.822.000 -1.64%
2018 1.824.000 -164.36%
2019 742.000 -145.82%
2020 1.544.000 51.94%
2021 -721.000 314.15%
2022 -908.000 20.59%
2023 140.000 748.57%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

IntelGenx Technologies Corp. Net Profit
Year Net Profit Growth
2003 -108
2004 -7.842 98.62%
2005 -11.123 29.5%
2006 -781.136 98.58%
2007 -1.100.846 29.04%
2008 -2.806.387 60.77%
2009 -1.940.400 -44.63%
2010 -3.096.000 37.33%
2011 -2.452.000 -26.26%
2012 -2.250.000 -8.98%
2013 -1.639.000 -37.28%
2014 -1.746.000 6.13%
2015 1.291.000 235.24%
2016 -1.180.000 209.41%
2017 -3.051.000 61.32%
2018 -10.108.000 69.82%
2019 -11.867.000 14.82%
2020 -8.246.000 -43.91%
2021 -9.312.000 11.45%
2022 -11.967.000 22.19%
2023 -11.036.000 -8.44%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

IntelGenx Technologies Corp. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

IntelGenx Technologies Corp. Free Cashflow
Year Free Cashflow Growth
2003 0
2004 0 0%
2005 0 0%
2006 -587.162 100%
2007 -1.051.669 44.17%
2008 -1.744.089 39.7%
2009 -1.610.900 -8.27%
2010 -2.617.000 38.44%
2011 -2.475.000 -5.74%
2012 -1.908.000 -29.72%
2013 -1.439.000 -32.59%
2014 -1.783.000 19.29%
2015 -2.834.000 37.09%
2016 -597.000 -374.71%
2017 -5.356.000 88.85%
2018 -9.626.000 44.36%
2019 -8.724.000 -10.34%
2020 -5.888.000 -48.17%
2021 -7.281.000 19.13%
2022 -9.787.000 25.61%
2023 -1.446.000 -576.83%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

IntelGenx Technologies Corp. Operating Cashflow
Year Operating Cashflow Growth
2003 0
2004 0 0%
2005 0 0%
2006 -489.651 100%
2007 -968.705 49.45%
2008 -1.737.032 44.23%
2009 -1.588.200 -9.37%
2010 -2.580.000 38.44%
2011 -2.316.000 -11.4%
2012 -1.638.000 -41.39%
2013 -1.173.000 -39.64%
2014 -1.380.000 15%
2015 546.000 352.75%
2016 1.729.000 68.42%
2017 -4.383.000 139.45%
2018 -8.530.000 48.62%
2019 -8.199.000 -4.04%
2020 -5.768.000 -42.15%
2021 -7.173.000 19.59%
2022 -9.516.000 24.62%
2023 -1.426.000 -567.32%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

IntelGenx Technologies Corp. Capital Expenditure
Year Capital Expenditure Growth
2003 0
2004 0 0%
2005 0 0%
2006 97.511 100%
2007 82.964 -17.53%
2008 7.057 -1075.63%
2009 22.700 68.91%
2010 37.000 38.65%
2011 159.000 76.73%
2012 270.000 41.11%
2013 266.000 -1.5%
2014 403.000 34%
2015 3.380.000 88.08%
2016 2.326.000 -45.31%
2017 973.000 -139.05%
2018 1.096.000 11.22%
2019 525.000 -108.76%
2020 120.000 -337.5%
2021 108.000 -11.11%
2022 271.000 60.15%
2023 20.000 -1255%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

IntelGenx Technologies Corp. Equity
Year Equity Growth
2003 -3.547
2004 -11.389 68.86%
2005 -22.012 48.26%
2006 328.079 106.71%
2007 211.874 -54.85%
2008 171.602 -23.47%
2009 2.157.000 92.04%
2010 1.476.000 -46.14%
2011 3.904.000 62.19%
2012 2.178.000 -79.25%
2013 5.008.000 56.51%
2014 4.573.000 -9.51%
2015 5.564.000 17.81%
2016 4.945.000 -12.52%
2017 3.829.000 -29.15%
2018 9.987.000 61.66%
2019 293.000 -3308.53%
2020 -953.000 130.75%
2021 3.871.000 124.62%
2022 -3.423.000 213.09%
2023 -10.906.000 68.61%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

IntelGenx Technologies Corp. Assets
Year Assets Growth
2003 0
2004 0 0%
2005 0 0%
2006 650.836 100%
2007 1.271.224 48.8%
2008 1.621.530 21.6%
2009 2.861.500 43.33%
2010 1.825.000 -56.79%
2011 4.570.000 60.07%
2012 4.159.000 -9.88%
2013 6.217.000 33.1%
2014 6.284.000 1.07%
2015 8.916.000 29.52%
2016 12.790.000 30.29%
2017 13.147.000 2.72%
2018 20.018.000 34.32%
2019 11.020.000 -81.65%
2020 11.118.000 0.88%
2021 17.905.000 37.91%
2022 9.190.000 -94.83%
2023 8.113.000 -13.27%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

IntelGenx Technologies Corp. Liabilities
Year Liabilities Growth
2003 3.547
2004 11.389 68.86%
2005 22.012 48.26%
2006 322.757 93.18%
2007 1.059.351 69.53%
2008 1.449.928 26.94%
2009 704.500 -105.81%
2010 349.000 -101.86%
2011 666.000 47.6%
2012 1.981.000 66.38%
2013 1.209.000 -63.85%
2014 1.711.000 29.34%
2015 3.352.000 48.96%
2016 7.845.000 57.27%
2017 9.318.000 15.81%
2018 10.031.000 7.11%
2019 10.727.000 6.49%
2020 12.071.000 11.13%
2021 14.034.000 13.99%
2022 12.613.000 -11.27%
2023 19.019.000 33.68%

IntelGenx Technologies Corp. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.1
Price to Earning Ratio
-1.74x
Price To Sales Ratio
37.8x
POCF Ratio
-3.47
PFCF Ratio
-3.42
Price to Book Ratio
-2.72
EV to Sales
55.14
EV Over EBITDA
-4.41
EV to Operating CashFlow
-5.07
EV to FreeCashFlow
-4.99
Earnings Yield
-0.57
FreeCashFlow Yield
-0.29
Market Cap
0,03 Bil.
Enterprise Value
0,04 Bil.
Graham Number
0.37
Graham NetNet
-0.09

Income Statement Metrics

Net Income per Share
-0.1
Income Quality
0.76
ROE
2.29
Return On Assets
-2.11
Return On Capital Employed
-2.43
Net Income per EBT
1.51
EBT Per Ebit
1.08
Ebit per Revenue
-13.28
Effective Tax Rate
-0.5

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
4.13
Stock Based Compensation to Revenue
0.38
Gross Profit Margin
-1.12
Operating Profit Margin
-13.28
Pretax Profit Margin
-14.37
Net Profit Margin
-21.73

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.05
Free CashFlow per Share
-0.05
Capex to Operating CashFlow
0.02
Capex to Revenue
-0.18
Capex to Depreciation
-0.18
Return on Invested Capital
-2.95
Return on Tangible Assets
-2.11
Days Sales Outstanding
323.67
Days Payables Outstanding
0
Days of Inventory on Hand
17.71
Receivables Turnover
1.13
Payables Turnover
0
Inventory Turnover
20.6
Capex per Share
-0

Balance Sheet

Cash per Share
0,01
Book Value per Share
-0,06
Tangible Book Value per Share
-0.06
Shareholders Equity per Share
-0.06
Interest Debt per Share
0.09
Debt to Equity
-1.42
Debt to Assets
1.91
Net Debt to EBITDA
-1.39
Current Ratio
0.84
Tangible Asset Value
-0,01 Bil.
Net Current Asset Value
-0,02 Bil.
Invested Capital
-1.42
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
82000
Debt to Market Cap
0.52

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

IntelGenx Technologies Corp. Dividends
Year Dividends Growth

IntelGenx Technologies Corp. Profile

About IntelGenx Technologies Corp.

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

CEO
Mr. Dwight Gorham
Employee
48
Address
6420 Abrams
Montreal, H4S 1Y2

IntelGenx Technologies Corp. Executives & BODs

IntelGenx Technologies Corp. Executives & BODs
# Name Age
1 Zenoz Nina Pourhassan
Vice President of Quality Operations of Subsidiary
70
2 Stephen Kilmer
Investor Relations Officer
70
3 Mr. Tommy Kenny J.D., L.L.B., M.Sc.
Senior Vice President & General Counsel
70
4 Mr. Dwight Gorham
Chief Executive Officer
70
5 Ms. Nadine Paiement
Vice-Chair of Scientific Advisory Board and Vice President of Research & Development - IntelGenx Corp
70
6 Ms. Ingrid Zerbe
Corporate Secretary
70
7 Mr. André Godin C.A., CPA, CA, CPA
President & Chief Financial Officer
70

IntelGenx Technologies Corp. Competitors